Logo image
Back
Brain Metastases in Patients with Gynecologic Cancers: A Single Institution Experience and Review of the Literature
Journal article   Open access

Brain Metastases in Patients with Gynecologic Cancers: A Single Institution Experience and Review of the Literature

Madiha A Gilani, Noelle L Williams, Carolyn Giordano, Norman Rosenblum, Wenyin Shi, Pramila Anne and Russell J Schilder
Open journal of obstetrics and gynecology, v 6(9), pp 544-552
01 Aug 2016
DOI: https://doi.org/10.4236/ojog.2016.69070
PMID: 31552146
url
https://doi.org/10.4236/ojog.2016.69070View
Published, Version of Record (VoR) Open

Abstract

Brain Metastasis Multimodality Therapy Gynecologic Malignancies Prognostic Factors
Brain Metastasis (BM) from primary gynecologic cancers is a rare entity. The advances and successes in the treatment of primary gynecologic malignancies, have led to prolonged survival and, a higher incidence of BM. This study aims to report the experience at our institution in managing these patients, and provide possible data points that may be essential to note as prognostic factors, and see if our findings are consistent with the literature in this subject. We also aim to provide a brief literature review of patients with gynecologic cancers and BM. This is a small single institution retrospective study of 23 patients with a gynecologic malignancy and BM, identified between the years 2007-2015. Data were collected on variables including patient demographics, disease and treatment. The median overall survival from the primary diagnosis was 28 months. Median time from diagnosis of BM to death was 9 months. The outcomes in our study are similar to what is stated in the current literature with regard to BM from gynecologic malignancies. Our literature search also revealed that the molecular analysis and treatment of the primary tumor remain important to prevent BMs. The tendency of tumors to metastasize varies for one tumor type to another for the same type of tumor. The tendency to develop BM may not only depend on risk factors such as stage, grade, and histology, but also on the genetic profile of the primary tumor. The study suggests that multimodal treatment of BM has better outcomes in managing BM from gynecologic cancers.

Metrics

5 Record Views

Details

Logo image